The implications for perioperative management of new oral antihyperglycemic medications and new insulin treatment technologies are reviewed.
INTRODUCTION
]. The perioperative period represents an ideal opportunity to identify patients with hyperglycemia with or without a diagnosis of diabetes, to optimize treatment of diabetes perioperatively, and to modify their postsurgical course.
The introduction of different classes of antihyperglycemic agents has made traditional recommendations to cease all treatment on the day of surgery over-simplistic. Newer agents such as sodium-glucose cotransporter 2 inhibitors (SGLT2i) may require longer periods of cessation prior to surgery. It may be safe to continue other drugs in patients with adequate renal function.
Advances in technology such as continuous glucose monitoring (CGM) systems and continuous subcutaneous insulin infusion therapy provides new opportunities for improving glycemic control but also carries new challenges. Ongoing work is required to determine their effectiveness in the acute setting.
Medications used to treat diabetes and its complications must be reviewed perioperatively with regard to effect on fluid homeostasis, electrolyte balance, cardiovascular stability, and with regard to interactions with common associated comorbidities such as renal failure, autonomic dysfunction, ischemic heart disease, vascular disease and hypertension.
Preoperative patient preparation and blood glucose targets
All patients presenting for surgery should be screened for diabetes. A recent measurement of Hemoglobin A1c (HbA1c) should be reviewed for all patients with diabetes preoperatively to allow for risk assessment and optimization of glycemic control (HbA1c) <69 mmol/mol) [2, 3] .
Several studies have demonstrated a relationship between glycemic control and adverse outcomes, although this not a simple relationship [4,5,6 & ,7] . A recent report is one of few prospective randomized trials demonstrating improved outcomes with preoperative diabetes optimization [8 & ] . A retrospective study suggests that improved preoperative diabetes control is associated with better pre and postsurgery glycemic control with reduced incidence of hypoglycemic events and reduction in length of stay [9 && ]. A meta-analysis of studies including only surgical patients with diabetes reported that perioperative blood glucose level (BGL) control of between 150 and 200 mg/ dl (8.3-11.1 mmol/l) was associated with reduced perioperative mortality and stroke compared with more liberal targets (BGL > 200 mg/dl; 11.1 mmol/l), but no additional benefit was gained from tighter control (101-150 mg/dl; 5.6-8.3 mmol/l) [10 & ]. Some studies have observed that perioperative hyperglycemia is more predictive of harm in patients without a previous diagnosis of diabetes [ 
KEY POINTS
The perioperative period is a key time to identify patients with hyperglycemia and provide management to improve the postsurgical course.
SGLT2i may provoke euglycemic diabetic ketoacidosis in the perioperative period and should be withheld until the patient is well and eating normally.
The American Diabetes Association (ADA) continues to recommend withholding metformin on the day of surgery [ Glucagon-like peptide-1 receptor agonists GLP-1 is an incretin hormone that promotes glucose-dependent insulin secretion, suppresses pancreatic glucagon production, slows gastric emptying and suppresses appetite. GLP-1 agonist medications are usually given by daily or weekly injection. Either withholding or continuing GLP-1RA therapy perioperatively period is clinically reasonable.
Insulin management
Discussion of perioperative management of insulin therapy should recognize the benefits of institutional consistency in clinical management and the need to avoid medication errors.
Basal bolus regimens for insulin administration are more successful than intermittent subcutaneous rapid acting insulin bolus regimens in achieving optimal BGL control in surgical patients with type 2 diabetes [61] . Basal bolus regimens are also associated with reduced postoperative complications and reduced inpatient costs per day [62 & ].
Variable rate intravenous insulin infusion (VRIII) has traditionally been limited to use in critical care settings, although multiple centers have been using VRIII safely and effectively based on nurse-led protocols in noncritical care settings for many years [63, 64] . British guidelines support the use of VRIII in noncritical care patients. The safety of these regimens relies on strict use of institutional protocols [65 & ].
Continuation of basal insulin at 80% of the usual dosage while fasting or on VRIII is recommended [2,12
& ]. Some modern basal insulins such as insulin degludec and insulin detemir bind to albumin. Degludec in particular forms a subcutaneous multimeric depot with biological activity exceeding 42 h [66] . There are limited studies to show how this impacts upon the perioperative glucose control although one study of patients undergoing fasting for colonoscopy did not demonstrate an increase in hypoglycemia [67] .
Advances in technology
Continuous glucose monitoring (CGM) of interstitial glucose, and automated insulin delivery devices, are now commonly used. Results suggest improvements in diabetes control with use of CGM, with greatest benefits seen with near-continuous use [68 & ]. Sensor-augmented pumps incorporate alarms to alert the user to actual or predicted hypoglycemia, with some devices ceasing insulin administration at certain thresholds. Hybrid closed-loop devices are now available. These systems employ an open loop for a patient-initiated premeal bolus but a computercontrolled closed loop for basal periods between meals and overnight, including hyperglycemiainitiated insulin dose increases. Embedded bolus calculators assist patients to manage their meal-time insulin requirements [ . However, it is worth noting that the accuracy of commercially available point-of-care blood glucose testing devices has been found to have wide variation in two recent studies, particularly in the hypoglycemic range. Many devices were not found to meet both international and US-based standards on meter accuracy. It is suggested this may be due to devices reaching the market prior to current, more stringent, standards being enacted, or due to postmarketing performance deterioration [72, 73] .
During ambulant and short-stay surgery, it may be appropriate to continue the use of advanced insulin pumps, in which the anesthesiologist (and the institution) is able and prepared to take temporary responsibility for managing the device. In other circumstances, the device should be removed and insulin infusion used instead.
Although some experts support the continuation of insulin pump use for minor procedures, some manufacturers advise that insulin pumps, and CGM sensors and transmitters, should not be used in association with MRI, computed tomography scanners, fluoroscopy and diathermy is being used [ 
Improving clinical processes, standards and quality
Despite the common focus on optimizing perioperative glycemic targets, the annual ADA 'Standards of 
CONCLUSION
Over recent years, consensus regarding appropriate perioperative glucose target has been reached although robust prospective evidence of improved surgical outcomes remains lacking. Optimal medication regimens should avoid severe hyperglycemia while also avoiding hypoglycemia with the latter being increasingly recognized as a significant contributor to length of stay, adverse outcomes and potentially mortality. Advances in technology provide opportunities for improved glycemic control but ongoing studies are required. The lack of familiarity with newer technology among healthcare workers remains a barrier to their use in acute care settings. Therapeutic complexity, patient and staff confusion, and medication errors may result in adverse clinical outcomes. Quality activities such as clinical standardization, audit and process improvement maybe the most important strategy to improve patient outcomes.
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